TherapeuticsMD (TXMD)
NASDAQ:TXMD
Want to see TXMD full AI Analyst Report?
TXMD Stock Chart & Stats
$1.68
-$0.07(-6.14%)
At close: 4:00 PM EST
$1.68
-$0.07(-6.14%)
Day’s Range― - ―
52-Week Range$0.98 - $2.95
Previous CloseN/A
Volume92.69K
Average Volume (3M)310.58K
Market Cap
$23.15M
Enterprise Value$23.69M
Total Cash (Recent Filing)$8.42M
Total Debt (Recent Filing)$5.83M
Price to Earnings (P/E)129.9
Beta1.15
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue7.06
Enterprise Value/Gross Profit7.82
Enterprise Value/Ebitda-6.38
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stable Balance SheetA modest debt-to-equity (~0.18 TTM) and consistently positive equity reduce solvency risk and give the company financial flexibility. Over 2-6 months this supports funding for operations, royalty monetization or strategic deals without heavy refinancing pressure.
Improving Cash GenerationReturn to positive operating and free cash flow with growth (~10.6% TTM) indicates better cash discipline and internal funding capacity. Durable cash generation reduces reliance on external capital and supports execution of strategic options or reinvestment.
Growing Royalty / License RevenueShifting toward an asset-light royalty model with meaningful license revenue growth (Mayne agreement) creates more predictable, high-margin cash streams. Structurally this can improve margins and scalability while lowering R&D and capex burden over time.
Bears Say
Declining TTM RevenueA 13% TTM revenue decline undermines revenue base needed to sustain fixed costs and long-term margin recovery. Persistent top-line contraction pressures operating leverage, making durable profitability and cashflow improvements harder to maintain.
Continued Negative Operating ProfitabilityDespite net income turning slightly positive, core operating profitability remains deeply negative. Reliance on non-operating gains or one-off items is risky; without sustained operating margin recovery, cash generation and return on capital may be fragile.
Strategic-transaction UncertaintyOngoing evaluation of M&A, asset sales or other transactions introduces execution and timing risk. Potential asset monetization could alter recurring royalty income, and lack of clarity hampers planning for investors, partners, and long-term strategy execution.
TherapeuticsMD News
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $0.98 and its highest was $2.95 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $23.15M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Aug 17, 2026 which is in 54 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on May 18, 2026. The company reported $0.008 earnings per share for the quarter, beating the consensus estimate of N/A by $0.008.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of $0.008 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Technical Analysis
Ownership Overview
1.56% Insiders
4.16% Mutual Funds
24.44% Other Institutional Investors
66.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---